Baby cucumbers and coconut water. Something called a protein pouch yoghurt. Welcome to the supermarket aisle in the era of Ozempic, the weight loss drug that since its introduction five years ago has done what decades of government policy could not: change how people eat.
Known as GLP-1 treatments, Ozempic and others like Wegovy and Mounjaro have transformed from specialist diabetes medications to blockbuster weight loss management tools by suppressing appetites and making users feel full. American pharmaceutical giant Eli Lilly is working on a new variant, one that threatens to accelerate the spread of GLP-1s by doing away with the need for an injection and delivering the drug in a pill.
Carrie LaFrenzSenior reporterCarrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
Simon EvansSenior reporterSimon Evans writes on business specialising in retail, manufacturing, beverages, mining and M&A. He is based in Adelaide. Connect with Simon on Twitter. Email Simon at simon.evans@afr.com
